Mini Review - Archives of Industrial Biotechnology (2022) Volume 7, Issue 1
Review on viral bioflims against SARS-CoV-2 (COVID-19).
Corona viruses are important human and animal pathogens. At the end of 2019, a novel coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei Province of China. It rapidly spread, resulting in an epidemic throughout China, followed by an increasing number of cases in other countries throughout the world. In February 2020, the World Health Organization designated the disease COVID-19, which stands for coronavirus disease 2019. The virus that causes COVID-19 is designated Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2); previously, it was referred to as 2019-nCoV. Today, efforts by various countries are based on the rapid diagnosis, isolation of patients and care that can combat the disease's most severe effects. The number of COVID-19 confirmed infections is still that. Unfortunately, no drugs or vaccines have been approved for the treatment of human coronaviruses but thorough research on emerging human infectious coronaviruses is urgently needed. The advancement of successful prevention and treatment strategies will be facilitated by clarification routes and pathogenic pathways and the identification of possible drug therapy targets. Due to public health emergencies, it is important to research the potential effects of therapeutic methods on SARSCoV-2 in the absence of established successful therapies. This review summarizes COVID-19's epidemiologic features, pathogenesis, virus structure and targeting strategies. In the meantime, this review also focuses on viral biofilms as a therapeutics effect that can be used to treat novel COVID-19.Author(s): Mennakshi Saravanan